PharmTech Drug Digest 11.20
News|Articles|April 4, 2016

BASF Extends Kollicoat Excipient Line

Kollicoat MAE 100-55 from BASF can be used as a direct substitute in commercial enteric pharmaceutical formulations.

Kollicoat MAE 100-55, introduced by BASF on April 4, 2016, is a functional excipient for instant and modified release drugs that can replace comparable pH >5.5 enteric release materials in commercial formulations, the company reports. The coating polymer matches the release profile and complies with applicable regulatory monographs and can be used without re-registration.

The size of the dried powder particles delivers dust-free handling, and the product provides equivalent drug release as existing comparable products in the market, according to a company statement.

Kollicoat MAE 100-55 extends the company’s pH >5.5 enteric release coatings based on methacrylic acid-ethylacrylate copolymer.

Source: BASF

 


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.